Cargando…
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
ABSTRACT: INTRODUCTION: Pre-clinical data suggest p53-dependent anthracycline-induced apoptosis and p53-independent taxane activity. However, dedicated clinical research has not defined a predictive role for TP53 gene mutations. The aim of the current study was to retrospectively explore the prognos...
Autores principales: | Fernández-Cuesta, Lynnette, Oakman, Catherine, Falagan-Lotsch, Priscila, Smoth, Ke-seay, Quinaux, Emmanuel, Buyse, Marc, Dolci, M Stella, Azambuja, Evandro De, Hainaut, Pierre, Dell'Orto, Patrizia, Larsimont, Denis, Francis, Prudence A, Crown, John, Piccart-Gebhart, Martine, Viale, Giuseppe, Leo, Angelo Di, Olivier, Magali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446332/ https://www.ncbi.nlm.nih.gov/pubmed/22551440 http://dx.doi.org/10.1186/bcr3179 |
Ejemplares similares
-
Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients
por: Haibe-Kains, B., et al.
Publicado: (2013) -
Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane
por: Ahn, Jin-Hee, et al.
Publicado: (2004) -
Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013) -
Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer
por: Veronese, Pedro, et al.
Publicado: (2018) -
The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)